Gonadotropin releasing hormone (GnRH) agonist therapy for reduction of leiomyoma volume.
A patient with menorrhagia, dysmenorrhea, and an enlarged uterus was treated with a GnRH agonist for leiomyoma volume reduction. A laser-assisted myomectomy yielded five tumors that did not appear to be well demarcated and had a combined weight of only 30 g. Postoperative pathologic evaluation revealed leiomyosarcoma with 22 mitoses per 10 high-power fields. The 8-month delay in therapy was associated with Stage IV, grade 3 disease at diagnosis. In rare cases GnRH agonist therapy may palliate symptoms and delay definitive surgical therapy of leiomyosarcoma, resulting in more advanced disease at diagnosis.
Murphy
N J
NJ
Department of Obstetrics and Gynecology, St. Luke's Hospital, Kansas City, Missouri 64111.
Wallace
D L
DL
D000328:Adult; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D016729:Leuprolide / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D016729:Leuprolide